Cargando…
CRISPR-Cas system: from diagnostic tool to potential antiviral treatment
ABSTRACT: This mini review focuses on the diagnosis and treatment of virus diseases using Crisper-Cas technology. The present paper describes various strategies involved in diagnosing diseases using Crispr-Cas-based assays. Additionally, CRISPR-Cas systems offer great potential as new therapeutic to...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411046/ https://www.ncbi.nlm.nih.gov/pubmed/36008567 http://dx.doi.org/10.1007/s00253-022-12135-2 |
_version_ | 1784775233060732928 |
---|---|
author | Rajan, Aishwarya Shrivastava, Stuti Janhawi Kumar, Akhilesh Singh, Alok Kumar Arora, Pankaj Kumar |
author_facet | Rajan, Aishwarya Shrivastava, Stuti Janhawi Kumar, Akhilesh Singh, Alok Kumar Arora, Pankaj Kumar |
author_sort | Rajan, Aishwarya |
collection | PubMed |
description | ABSTRACT: This mini review focuses on the diagnosis and treatment of virus diseases using Crisper-Cas technology. The present paper describes various strategies involved in diagnosing diseases using Crispr-Cas-based assays. Additionally, CRISPR-Cas systems offer great potential as new therapeutic tools for treating viral infections including HIV, Influenza, and SARS-CoV-2. There are several major challenges to be overcome before this technology can be applied routinely in clinical settings, such as finding a suitable delivery tool, toxicity, and immunogenicity, as well as off-target effects. This review also discusses ways to deal with the challenges associated with Crisper-Cas technology. KEY POINTS: • Crisper technology is being applied to diagnose infectious and non-infectious diseases. • A new generation of CRISPR-Cas-based assays has been developed which detect pathogens within minutes, providing rapid diagnosis of diseases. • Crispr-Cas tools can be used to combat viral infections, specifically HIV, influenza, and SARS-CoV-2. |
format | Online Article Text |
id | pubmed-9411046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-94110462022-08-26 CRISPR-Cas system: from diagnostic tool to potential antiviral treatment Rajan, Aishwarya Shrivastava, Stuti Janhawi Kumar, Akhilesh Singh, Alok Kumar Arora, Pankaj Kumar Appl Microbiol Biotechnol Mini-Review ABSTRACT: This mini review focuses on the diagnosis and treatment of virus diseases using Crisper-Cas technology. The present paper describes various strategies involved in diagnosing diseases using Crispr-Cas-based assays. Additionally, CRISPR-Cas systems offer great potential as new therapeutic tools for treating viral infections including HIV, Influenza, and SARS-CoV-2. There are several major challenges to be overcome before this technology can be applied routinely in clinical settings, such as finding a suitable delivery tool, toxicity, and immunogenicity, as well as off-target effects. This review also discusses ways to deal with the challenges associated with Crisper-Cas technology. KEY POINTS: • Crisper technology is being applied to diagnose infectious and non-infectious diseases. • A new generation of CRISPR-Cas-based assays has been developed which detect pathogens within minutes, providing rapid diagnosis of diseases. • Crispr-Cas tools can be used to combat viral infections, specifically HIV, influenza, and SARS-CoV-2. Springer Berlin Heidelberg 2022-08-26 2022 /pmc/articles/PMC9411046/ /pubmed/36008567 http://dx.doi.org/10.1007/s00253-022-12135-2 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Mini-Review Rajan, Aishwarya Shrivastava, Stuti Janhawi Kumar, Akhilesh Singh, Alok Kumar Arora, Pankaj Kumar CRISPR-Cas system: from diagnostic tool to potential antiviral treatment |
title | CRISPR-Cas system: from diagnostic tool to potential antiviral treatment |
title_full | CRISPR-Cas system: from diagnostic tool to potential antiviral treatment |
title_fullStr | CRISPR-Cas system: from diagnostic tool to potential antiviral treatment |
title_full_unstemmed | CRISPR-Cas system: from diagnostic tool to potential antiviral treatment |
title_short | CRISPR-Cas system: from diagnostic tool to potential antiviral treatment |
title_sort | crispr-cas system: from diagnostic tool to potential antiviral treatment |
topic | Mini-Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411046/ https://www.ncbi.nlm.nih.gov/pubmed/36008567 http://dx.doi.org/10.1007/s00253-022-12135-2 |
work_keys_str_mv | AT rajanaishwarya crisprcassystemfromdiagnostictooltopotentialantiviraltreatment AT shrivastavastuti crisprcassystemfromdiagnostictooltopotentialantiviraltreatment AT janhawi crisprcassystemfromdiagnostictooltopotentialantiviraltreatment AT kumarakhilesh crisprcassystemfromdiagnostictooltopotentialantiviraltreatment AT singhalokkumar crisprcassystemfromdiagnostictooltopotentialantiviraltreatment AT arorapankajkumar crisprcassystemfromdiagnostictooltopotentialantiviraltreatment |